PCSK9 inhibitor (AstraZeneca)

N/A

Report date: 2025/01/26 19:22:17
NME

Base Information

Drug NamePCSK9 inhibitor (AstraZeneca)
Drug Alias NamePCSK9 inhibitor (Dogma Therapeutics/Charles River Laboratories)PCSK9 inhibitor (Dogma Therapeutics/Charles River Laboratories)proprotein convertase subtilisin/kexin type 9 inhibitor (Dogma Therapeutics/Charles River Laboratories)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHypercholesterolemiaCardiovascular Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesDogma Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Plc
Inactive CompaniesDogma Therapeutics
Active IndicationsHypercholesterolemiaCardiovascular Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A